Centessa Pharmaceuticals plc
HealthcareNASDAQ:CNTA · NASDAQ Global Select
-$0.03 today
Vol 1.12M · Avg 2.59M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.5%
avg -92.3%
ROIC
-32.2%
avg -50.1%
ROA
-28.7%
avg -44.6%
Analysis
ROA is currently the strongest return metric at -28.7% versus its period average of -44.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mario Alberto Accardi | Chief Executive Officer & Director | $1.23M | — | 40 | $243,282.00 | 0.16% |
John J. Crowley | Chief Financial Officer | $853,860.00 | — | 52 | $181,000.00 | 0.12% |
Stephen J. Kanes | Head of R&D and Chief Medical Officer | $823,800.00 | — | 61 | $120,000.00 | 0.08% |
Iqbal J. Hussain | Chief Legal Officer, Chief Compliance Officer & Company Secretary | $768,575.00 | — | 45 | $160,000.00 | 0.10% |
Gregory Weinhoff | Chief Business Officer | $655,004.00 | — | 55 | $89,923.00 | 0.06% |
Charlene Stoudt | Senior Vice President of Clinical Development Operations | — | — | — | — | — |
Raphael Deferiere | Senior VP & Chief Accounting Officer | — | — | 46 | $42,000.00 | 0.03% |
Karen Anderson | Chief People Officer | — | — | 58 | $62,085.00 | 0.04% |
Kristen K. Sheppard | Senior Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
Tia L. Bush | Chief Technology & Quality Officer | — | — | 55 | $147,954.00 | 0.10% |
Kimberly A. McCormick | Senior Vice President of Regulatory Affairs & Medical Writing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
36
$19.13M
Net Sentiment
$19.13M
Net selling
Most Active
HUSSAIN IQBAL J
10 transactions
1–10 of 36
Analysis
Insiders reported 0 buys worth $0.00 and 36 sells worth $19.13M over the last 12 months. That adds up to net selling of $19.13M. HUSSAIN IQBAL J was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +101.6% (7yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +101.6% (7yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.67B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.45B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.28B
Celcuity Inc.
NASDAQ:CELC
$4.34B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
Zai Lab Limited
NASDAQ:ZLAB
$1.93B
Ascentage Pharma Group International
NASDAQ:AAPG
$415.08M
Who manages CNTA?
Centessa Pharmaceuticals plc (CNTA) lists 11 active executives. The top listed executive is Charlene Stoudt, Senior Vice President of Clinical Development Operations.
Are CNTA insiders buying or selling?
Recent insider activity shows net buying of $44.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.